Parameterization of Org27569: An allosteric modulator of the cannabinoid CB1 G protein-coupled receptor
✍ Scribed by Hadley A. Iliff; Diane L. Lynch; Evangelia Kotsikorou; Patricia H. Reggio
- Book ID
- 102877005
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 959 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0192-8651
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The cannabinoid CB~1~ receptor is a class A G protein‐coupled receptor (GPCR) that is the most widely expressed GPCR in the brain. Many GPCRs contain allosteric binding sites for endogenous and/or synthetic ligands, which are topographically distinct from the agonist‐binding site that is known as the orthosteric site. While both endogenous and synthetic ligands that act at the CB~1~ orthosteric site have been known for some time, compounds that act at a CB~1~ allosteric site have only recently been discovered. The most studied of these is 5‐chloro‐3‐ethyl‐1H‐indole‐2‐carboxylic acid [2‐(4‐piperidin‐1‐ylphenyl)ethyl]amide (Org27569). Because allosteric ligands are thought to act through conformational changes in the receptor that are transmitted from the allosteric to the orthosteric site, computational studies of the structural and dynamic interactions of Org27569 with the CB~1~ receptor are crucial to achieve a molecular level understanding of the basis of action of this important new class of compounds. To date, such computational studies have not been possible due to the lack of a complete set of molecular mechanics force field parameters for Org27569. Here, we present the development of missing CHARMM force field parameters for Org27569 using previously published methods and the validation and application of these new parameters using normal mode analysis and molecular dynamics simulations combined with experimental infrared measurements. © 2011 Wiley Periodicals, Inc. J Comput Chem, 2011
📜 SIMILAR VOLUMES
The present study was designed to test whether chronic neuroleptic treatment, which is known to alter both expression and density of dopamine D 2 receptors in striatal regions, has effects upon function and binding level of the cannabinoid CB 1 receptor in the basal ganglia by using receptor autorad